DERIVATION AND VALIDATION OF THE NIS2+™ BLOOD-BASED BIOMARKER PANEL, AN IMPROVEMENT OF NIS4® TECHNOLOGY FOR THE IDENTIFICATION OF AT-RISK NASH
Combination of noninvasive prognostic biomarkers, corrected T1 and enhanced liver fibrosis test, for the enrichment of at-risk nonalcoholic steatohepatitis or advanced fibrosis
Machine Learning Algorithm to Detect Shear Waves During Velacur™ Exams
Identification of at-risk nonalcoholic steatohepatitis in lean individuals with multiparametric magnetic resonance imaging biomarker, corrected T1
Dependence of PDFF Measurement Accuracy on Location, Resolution, and Field Strength
A BIOMARKER OF FIBROSIS RESOLUTION, CTX-III, INCREASES AFTER BARIATRIC SURGERY IN EARLY NAFLD PATIENTS WITH HISTOLOGICAL LIVER IMPROVEMENTS
COMPARING CARDIOVASCULAR AND INFECTION COMPLICATIONS IN LIVER TRANSPLANT PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS VERSUS OTHER INDICATIONS
Introduction of NAFLD/NASH genetic risk factors PNPLA3-I148M and TM6SF2-E167K in HepaRG cells reveals distinct metabolic profiles in high-throughput organ-on-a-chip system.
Comparative Efficacy of DA-1726, a Novel Oxyntomodulin Analogue, with Semaglutidein a Diet-Induced NASH Mouse Model
Resolving Cell Type-specific Transcriptional Response and GalNAc-ASO Targeting in Liver Cells for the Treatment of NASH
Simultaneous activation of glucagon, GIP, and GLP-1 by efocipegtrutide (HM15211) could provide improved anti-inflammatory and anti-fibrotic effects in thioacetamide-induced mouse model of livery injury and fibrosis
CORRELATION OF P-P38 MODULATION WITH ANTI-INFLAMMATORY AND ANTI-FIBROTIC EFFICACY BY SRT-015 BUT NOT SELONSERTIB
Serum metabolomic, lipidomic and proteomic profiling identifies new biomarkers associated with the treatment of denifanstat, a fatty acid synthase inhibitor, in NASH patients
Rencofilstat Multiomics Indicate Clinically Important Mechanisms in NAFLD-NASH.
DENIFANSTAT (DEN), A FIRST IN CLASS FATTY ACID SYNTHASE (FASN) INHIBITOR, SIGNIFICANTLY REDUCES PLASMA TRIPALMITIN, A MARKER OF DE NOVO LIPOGENESIS, IN NASH PATIENTS IN THE FASCINATE 1 AND FASCINATE 2 CLINICAL STUDIES
EFFICACY, SAFETY, AND TOLERABILITY OF CONTINUED LPCN 1144 TREATMENT IN NONALCOHOLIC STEATOHEPATITIS (NASH) SUBJECTS WITH FIBROSIS IN AN OPEN LABEL EXTENSION STUDY
Pegozafermin Led to Significant Metabolic Benefits, in Addition to Robust Beneficial Effects on the Liver, in an Open-label Cohort of a Phase 1b/2a Study in Subjects with Non-alcoholic Steatohepatitis (NASH)
Hepatic fat and liver volume reductions impact on non-alcoholic steatohepatitis trials and potential solutions using qFibrosis and qBallooning
Prevalence of esophageal and gastric varices in patients with compensated non alcoholic steatohepatitis (NASH) cirrhosis and portal hypertension. Data from the NAVIGATE study
Focused monitoring and management guidance reduces the incidence of hepatic safety events: Results from the phase 3 REGENERATE trial of obeticholic acid for nonalcoholic steatohepatitis
All Copyright © Reserved by MASH-TAG
Internet Explorer is not supported by this site.
Please consider using Google Chrome or Microsoft Edge instead.
